Home / Healthcare/ FDA clears Novo Nordisk’s diabetes drug to reduce cardiovascular risk

FDA clears Novo Nordisk’s diabetes drug to reduce cardiovascular risk


Comments / {{hitsCtrl.values.hits}} Views / Monday, 28 August 2017 00:09


Reuters: Novo Nordisk said on Friday the US Food and Drug Administration (FDA) approved an expanded use of its diabetes drug to reduce the risk of cardiovascular events such as heart attack and stroke.

1Novo Nordisk logo is seen in Bagsvaerd outside of Copenhagen, Denmark – REUTERS

This is the first time the FDA has cleared a diabetes drug for reducing risks of heart attack, stroke and cardiovascular deaths in patients with type 2 diabetes, the company said in a statement.

In December, the FDA had approved Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc’s drug, Jardiance, to reduce the risk of cardiovascular death in patients with type 2 diabetes.

Novo Nordisk’s Victoza, which was approved in 2010 to treat patients with type 2 diabetes, brought in 11.5 billion Danish crown ($1.84 billion) in the first six months of 2017.

Type 2 diabetes, closely linked to obesity, accounts for more than 90% of all diabetes cases, the company said.

Victoza’s expanded label follows a successful trial that showed the drug significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13% when compared to a placebo.

Heart disease is the leading cause of death in the United States, killing about 610,000 people every year, according to the Centers for Disease Control and Prevention.

Adults with type 2 diabetes are up to four times more likely to develop cardiovascular disease, the company said.


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

To hang or not to hang!

Tuesday, 17 July 2018

President Maithripala Sirisena dropped a bombshell out of the blues last week, sans all ‘maître’ (loving-kindness) when he launched a coup de main on drug offenders. He threatened to use his powers to place his signature to execute the death sen


The demise of the superstar investor

Tuesday, 17 July 2018

The allure of the superstar investor can be irresistible. You know who they are – the confident, articulate individuals idolised either because of a spectacular non-consensus investment call, the size of their fortune or sometimes because they are


Disruptive economy and poverty of knowledge: Sri Lankans have a lot to learn

Monday, 16 July 2018

The poor are usually defined as those who are below a given level of income that would be insufficient to meet their basic needs. In my view, the poor – no matter whether it is an individual, family or a nation – are those who are unable to read


National prosperity through quality and productivity

Monday, 16 July 2018

I was so delighted to get involved with the national convention of the Sri Lanka Association for the Advancement of Quality and Productivity (SLAAQP) with the fitting theme, “National Prosperity through World Class Quality and Productivity”.


Columnists More